A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

(2018) Ghassan K. Abou-Alfa et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours

(2017) Patrick Schöffski et al.   EUROPEAN JOURNAL OF CANCER

Intracranial Activity of Cabozantinib in MET Exon 14–Positive NSCLC with Brain Metastases

(2017) Samuel J. Klempner et al.   Journal of Thoracic Oncology

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy

(2017) Patrick Y Wen et al.   NEURO-ONCOLOGY

Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study

(2016) Sara M. Tolaney et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma

(2016) Jayashree Kalpathy-Cramer et al.   JOURNAL OF NEURO-ONCOLOGY

Phase II and Biomarker Study of Cabozantinib in Metastatic Triple‐Negative Breast Cancer Patients

(2016) Sara M. Tolaney et al.   ONCOLOGIST

Bevacizumab Preconditioning Followed by Etoposide and Cisplatin Is Highly Effective in Treating Brain Metastases of Breast Cancer Progressing from Whole-Brain Radiotherapy

(2015) Y.-S. Lu et al.   CLINICAL CANCER RESEARCH

Lessons From Anti–Vascular Endothelial Growth Factor and Anti–Vascular Endothelial Growth Factor Receptor Trials in Patients With Glioblastoma

(2015) Christine Lu-Emerson et al.   JOURNAL OF CLINICAL ONCOLOGY

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Toni K. Choueiri et al.   NEW ENGLAND JOURNAL OF MEDICINE

Metastatic breast cancer subtypes and central nervous system metastases

(2014) C. Aversa et al.   BREAST

Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study

(2013) A. X. Zhu et al.   CLINICAL CANCER RESEARCH

Cabozantinib in Progressive Medullary Thyroid Cancer

(2013) Rossella Elisei et al.   JOURNAL OF CLINICAL ONCOLOGY

At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy

(2013) Andrew M. Intlekofer et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases

(2012) D. P. Kodack et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Glioblastoma Recurrence after Cediranib Therapy in Patients: Lack of "Rebound" Revascularization as Mode of Escape

(2011) E. di Tomaso et al.   CANCER RESEARCH

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

(2011) F. M. Yakes et al.   MOLECULAR CANCER THERAPEUTICS

The biology of brain metastases—translation to new therapies

(2011) April F. Eichler et al.   Nature Reviews Clinical Oncology

HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors

(2010) F. Shojaei et al.   CANCER RESEARCH

A Fully Automated Method for Quantitative Cerebral Hemodynamic Analysis Using DSC–MRI

(2010) Atle Bjørnerud et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

(2009) John M.L. Ebos et al.   CANCER CELL

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

Biomarkers of response and resistance to antiangiogenic therapy

(2009) Rakesh K. Jain et al.   Nature Reviews Clinical Oncology